Business Wire

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial

19.11.2026 14:00:00 CET | Business Wire | Press Release

Share

GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an alternative to – or even replace – gadolinium-based contrast agents (GBCAs), the current standard of care. This is because of their potential to address concerns with gadolinium-based contrast agents around retention in the body, supply chain resiliency, and the environment. This milestone comes seven months after the first patient was dosed at Mayo Clinic in April 2026, and builds on Phase 1 results showing the agent was well tolerated.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119117575/en/

Representative pre- and post-mangaciclanol images in patients from the LUMINA Phase 2/3 trial

The Phase 2 stage of the adaptive Phase 2/3 trial design is a dose-finding study in adult patients with known or highly suspected lesions referred for contrast-enhanced MRI of the central nervous system. Participants received both mangaciclanol and gadobutrol, a gadolinium-based agent, with their images compared side by side by blinded independent readers. The primary endpoint, overall diagnostic preference, was met, with diagnostic preference similar between mangaciclanol and gadobutrol. Lesion visualization and quantitative imaging findings were generally similar, and mangaciclanol was well tolerated, with no safety concerns identified following its administration. Safety will continue to be evaluated in Phase 3. LUMINA is being conducted at clinical sites in the United States, Europe and Asia.

Dr Robert J. McDonald, M.D., Ph.D., neuroradiologist at Mayo Clinic, U.S., and one of the principal investigators of the LUMINA study, said, "For years, clinicians and patients have asked whether we can achieve the diagnostic confidence of gadolinium without the concerns around tissue retention and nephrogenic systemic fibrosis risk. These Phase 2 results are an important step toward answering that question. Seeing a manganese-based agent perform this well under blinded comparison with an established gadolinium agent is encouraging, and I look forward to what Phase 3 will show across a broader range of patients."

Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics (PDx), GE HealthCare, said, “These positive Phase 2 results support dose selection for Phase 3, which will further evaluate the efficacy and safety of mangaciclanol-enhanced MRI for detecting and characterizing lesions of the central nervous system and body. As aging populations and the rising burden of chronic disease drive demand for imaging, we continue to invest in our contrast media portfolio and in what comes next. Manganese-based contrast agents have the potential to transform the MRI market, helping meet the evolving needs of clinicians and patients.”

Approximately one-third of global MRI procedures require a contrast agent,1 and around 65 million contrast-enhanced procedures are performed globally each yearusing GBCAs as the current standard of care.2 Unlike gadolinium, manganese is an endogenous element, present in our food, and naturally occurring and autoregulated in the body. Mangaciclanol's macrocyclic "cage-like" structure is designed to minimize the possibility of retention in the body. Gadolinium is a rare-earth metal largely dependent on mining and processing infrastructure in China, whereas manganese is an essential element abundantly available from multiple countries. Furthermore, as manganese is naturally found in water sources, MBCAs could reduce environmental concerns associated with excreted contrast agents.

Mangaciclanol has received Fast Track designation by the U.S. Food and Drug Administration (FDA), which expedites the review of new therapeutics and medical imaging agents that have the potential to address significant unmet patient needs. Mangaciclanol is an investigational agent and is not currently approved for use by the FDA or any other regulatory authority. Its safety and efficacy have not been established.

GE HealthCare’s PDx segment is a global leader in imaging agents used to support 140 million patient procedures per year globally,3 equivalent to four procedures every second. For more than 40 years, GE HealthCare contrast media has been routinely used across MR, X-ray, CT and ultrasound to enhance clinical images and support diagnosis.

GE HealthCare will present preliminary Phase 2 trial results with clinical images, at RSNA in McCormick Place, Chicago, on Tuesday 1 December 12:00-13:00 at the Industry Expert Theater in South Hall A.

References:

  1. Contrast Agents of Magnetic Resonance Imaging and Future Perspective. Nanomaterials. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC10343825/
  2. Recent Developments and Future Perspectives in Magnetic Resonance Imaging and Computed Tomography Contrast Media. Investigative Radiology. Available at: https://pmc.ncbi.nlm.nih.gov/articles/PMC12871431/
  3. GE HealthCare press release: GE HealthCare Invests $138 Million in Cork, Ireland Manufacturing Facility to Address Increasing Contrast Media Demand

About GE HealthCare Technologies Inc.

GE HealthCare is a leading global healthcare solutions provider of advanced medical technology, pharmaceutical diagnostics, and AI, cloud and software solutions that help clinicians tackle the world’s most complex diseases. Serving patients and providers for 130 years, GE HealthCare is delivering bold innovations designed for the next era of medicine across its Advanced Imaging Solutions, Pharmaceutical Diagnostics and Patient Care Solutions segments to help clinicians deliver more personalized, precise patient care. We are a $20.6 billion business with approximately 54,000 colleagues working to create a world where healthcare has no limits.

GE HealthCare is proud to be among 2026 Fortune World’s Most Admired Companies™.

Follow us on LinkedIn, Facebook, Instagram, or visit our website for our latest news and perspectives.

Forward-Looking Statements

This release contains forward-looking statements. These forward-looking statements might be identified by words, and variations of words, such as “will,” “expect,” “may,” “would,” “could,” “plan,” “believe,” “anticipate,” “intend,” “estimate,” “potential,” “position,” and similar expressions. These forward-looking statements may include, but are not limited to, statements about the transaction, the completion and expected results of the transaction including the financial performance of the business, industry positioning, and GE HealthCare Technologies Inc.’s (“the Company’s”) business, products, growth opportunities, and strategy. These forward-looking statements involve risks and uncertainties, many of which are beyond the control of the Company. Factors that could cause the Company’s actual results to differ materially from those described in its forward-looking statements include, but are not limited to, the conditions to the completion of the transaction may not be satisfied; closing of the transaction may not occur or may be delayed; the Company may be unable to achieve the anticipated benefits of the transaction; operating costs and business disruptions (including, without limitation, difficulties in maintaining relationships with employees, customers, and suppliers) may be greater than expected; the Company may assume unexpected risks and liabilities; and completing the transaction may distract the Company’s management from other important matters. Other factors that may cause such a difference also include those discussed in the "Risk Factors" section of the Company’s Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission and any updates or amendments it makes in future filings. There may be other factors not presently known to the Company or which it currently considers to be immaterial that could cause the Company’s actual results to differ materially from those projected in any forward-looking statements the Company makes. The Company does not undertake any obligation to update or revise its forward-looking statements except as required by applicable law or regulation.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261119117575/en/

Contacts

GE HealthCare Media Contact:
Polly Beaumont
M +44 7345 776251
polly.beaumont@gehealthcare.com

(c) 2024 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Xsolla Gives Games a New Home for Their Players on Desktop and the Web, With Rewards to Help Bring Players Back19.11.2026 15:32:00 CET | Press Release

Xsolla (USA), Inc., a global commerce company, is giving game developers two new capabilities designed to reach players and encourage repeat engagement. Xsolla Player and Xsolla Pages are now available, letting developers integrate quests, rewards, and partner-funded offers into the player flow. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119175727/en/ Graphic: Xsolla Xsolla Player is a desktop app that players install once and access with their Xsolla ID, bringing their game library and inventory together without separate sign-ups for each game. Xsolla Pages creates search-optimized storefronts on the web for every title in a developer’s catalog, with direct checkout. PC studios work hard to win a player's first click, then work just as hard for every session after. Bringing players back is a challenge and has traditionally required paying to reach them again. Meanwhile, direct web sales have become a major revenue ch

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press Release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press Release

Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts interested in attending the Investor Day in person may contact Rimini Street Investor Relations IR@riministreet.com for an event invitation and details. In-person space is limited and will be followed by a networking lunch with Rimini Street senior executives and client attendees. Webcast

Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector19.11.2026 15:00:00 CET | Press Release

Belkin, a leading consumer electronics brand for over 40 years, today announced that its Titan SmartShield Pro Bright Privacy Screen Protector has been named a CES Innovation Awards® 2027 Honoree in the Mobile Devices, Accessories & Apps category. The recognition celebrates Belkin's innovative approach to screen protection, combining enhanced privacy, optical clarity and durability without compromising the everyday smartphone experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119118768/en/ Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector The CES Innovation Awards® 2027 program received a record number of submissions – nearly 4,000 – ahead of CES 2027, taking place January 6–9 in Las Vegas. The annual competition, owned and produced by the Consumer Technology Association (CTA)®, recognizes outstanding design and engineering across 37 technology product categ

Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press Release

Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye